Welcome visitor Log In - or - Register
0 items /
View Cart
Check Out
four ways
Quick Search:
Skip Navigation LinksHome > Kinase Inhibitors > Erk (Extracellular signal regulated kinase) > Ulixertinib (BVD-523, VRT752271)
Ulixertinib (BVD-523, VRT752271)
Ulixertinib (BVD-523, VRT752271) is a cell permeable small-molecule ERK1/2 kinase inhibitor currently under clinical investigation (Phase 1). It potently and selectively inhibits ERK1 and ERK2 kinases in a reversible, ATP-competitive fashion. Inhibits signal transduction, cell proliferation, and cell survival, most potently in cell lines bearing mutations that activate MAPK pathway signaling. Single-agent Ulixertinib inhibits tumor growth in vivo in BRAF-mutant melanoma and colorectal xenografts as well as in KRAS-mutant colorectal and pancreatic models. Combination treatment with Ulixertinib and Dabrafenib inhibits tumor growth in a BRAF-mutant melanoma model.
Catalog NO: CT-VRT752
Synonym: BVD-523, VRT752271
CAS NO: 1956366-10-1
Mol. Formula: C21H22Cl2N4O2 ∙ HCl
MW: 469.8
** in vivo Quality material. 99.9% by achiral and chiral HPLCs (Attached). HCl salt, Clinical Formulation Format (Ref. 2), Validated by a spot-on Quantitative microanalysis. Bulk Stock! Same day shipping.